GleamWall
中文EN

CSCIF COSCIENS Biopharma Inc. IFRS

Perfumes, Cosmetics & Other Toilet Preparations · OTC · SEC CIK 1113423 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-21.8%
TTM net income YoY32.3%
TTM EPS YoY44.9%
Revenue 3-yr CAGR-19.9%
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-142.5%
Net margin-138.1%
FCF margin-122.4%
EBITDA margin-126.6%

Returns

ROE-121.8%
ROA-36.7%
ROIC (approx.)—
Asset turnover0.27x

Leverage & solvency

Liabilities / assets82.1%
Debt / equity0.00x
Current ratio3.18x
Interest coverage-63.58x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue9.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$7.50M$9.59M$7.14M$14.57M$5.26M
Cost of revenue$4.85M$4.86M$4.21M$6.02M$90,000
Gross profit$2.65M$4.73M$2.94M$8.56M$5.17M
R&D expense$2.95M$8.30M$2.04M$1.37M$6.57M
SG&A expense$10.06M$10.45M$5.53M$2.87M$7.27M
Operating income-$10.68M-$18.28M-$4.63M$4.32M-$8.67M
Interest expense$168,000$129,000$136,000$143,000—
Pretax income-$10.35M-$15.22M-$4.37M$4.53M-$8.48M
Income tax$10,000$84,000-$885,000$1.08M-$109,000
Net income-$10.36M-$15.31M-$3.48M$3.45M-$8.37M
EBITDA-$9.49M-$16.67M-$3.19M$5.79M-$8.53M
EPS (basic)-3.27-5.93-1.891.87-1.82
EPS (diluted)-3.27-5.93-1.891.86-1.82
Weighted avg. shares (diluted)3.17M2.58M1.85M1.85M4.60M
Balance sheet
Cash & equivalents$7.31M$16.39M$6.68M$10.19M$6.16M
Receivables$1.26M$2.36M$290,000$732,000$1.31M
Inventory$1.31M$2.69M$4.01M$229,000—
Current assets$11.50M$23.98M$11.27M$55.49M$70.82M
PP&E, netmay include right-of-use assets (IFRS)$9.81M$10.97M$10.97M$216,000$192,000
Goodwill————$8.13M
Intangibles——$7,000$9,000$625,000
Total assets$21.43M$35.07M$23.75M$27.84M$80.10M
Current liabilities$3.61M$7.22M$1.31M$7.04M$7.77M
Total liabilities$17.59M$21.91M$2.71M$4.02M$27.12M
Shareholders' equity$3.84M$13.16M$21.04M$23.82M$21.94M
Cash flow statement
Operating cash flow-$8.47M-$14.57M-$2.58M$5.23M-$8.58M
Capital expenditure$706,000$1.16M$722,000$304,000$30,000
Free cash flow-$9.18M-$15.73M-$3.30M$4.92M-$8.61M
Investing cash flow-$458,000$25.08M-$730,000-$304,000-$658,000
Financing cash flow-$407,000-$588,000-$357,000-$267,000$51.04M
Depreciation & amortization$1.19M$1.61M$1.44M$1.47M$144,000
Stock-based compensation-$12,000$464,000$192,000$69,000$311,000

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.